公开(公告)号：US20170088615A1

公开(公告)日：2017-03-30

申请号：US15288545

申请日：2016-10-07

申请人： E.R. SQUIBB & SONS, L.L.C. ,  Ono Pharmaceutical Co., LTD.

发明人： Alan J. KORMAN ,  Mohan SRINIVASAN ,  Changyu WANG ,  Mark J. SELBY ,  Bingliang CHEN ,  Josephine M. CARDARELLI ,  Haichun HUANG

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61K39/00

摘要： The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.

公开(公告)号：US20230272079A1

公开(公告)日：2023-08-31

申请号：US18167012

申请日：2023-02-09

申请人： E.R. SQUIBB & SONS, L.L.C. ,  Ono Pharmaceutical Co., LTD.

发明人： Alan J. KORMAN ,  Mohan SRINIVASAN ,  Changyu WANG ,  Mark J. SELBY ,  Bingliang CHEN ,  Josephine M. CARDARELLI ,  Haichun HUANG

IPC分类号： C07K16/28 ,  A61P7/06 ,  A61K47/68 ,  C07K16/18 ,  A61K39/395 ,  C07K16/46 ,  A61K51/10 ,  A61K39/00

CPC分类号： C07K16/2818 ,  A61P7/06 ,  A61K47/6849 ,  C07K16/18 ,  A61K39/3955 ,  C07K16/468 ,  A61K51/10 ,  C07K16/28 ,  A61K39/39558 ,  A61K39/00 ,  C07K16/2803 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/52 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/732 ,  Y02A50/30 ,  C07K2317/73 ,  A61K2039/507 ,  C07K2317/33 ,  C07K2317/92 ,  C07K2317/94

摘要： The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.

公开(公告)号：US20160304596A1

公开(公告)日：2016-10-20

申请号：US15136832

申请日：2016-04-22

申请人： AMGEN INC. ,  E.R. SQUIBB & SONS, L.L.C.

发明人： Kenneth D. WILD, Jr. ,  James J.S. TREANOR ,  Haichun HUANG ,  Heather INOUE ,  Tie J. ZHANG ,  Frank MARTIN

IPC分类号： C07K16/22 ,  G01N33/74

CPC分类号： C07K16/22 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/74 ,  G01N2333/48 ,  G01N2800/2842

摘要： This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.